We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioGenes Reports Strong Growth of HCP Assay Development Business
News

BioGenes Reports Strong Growth of HCP Assay Development Business

BioGenes Reports Strong Growth of HCP Assay Development Business
News

BioGenes Reports Strong Growth of HCP Assay Development Business

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioGenes Reports Strong Growth of HCP Assay Development Business"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioGenes GmbH announced a strong increase in sales volume in 2012, the year of the company’s 20th anniversary, due to a high demand of specific antibodies and ELISA assays used in drug development processes. In particular, the HCP assay development business showed a remarkable growth increasing by 36% over 2011.

BioGenes is a recognized partner of pharmaceutical companies all over the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.

“Our long-term strategy to focus on HCP assay development pays off and we expect the growth to continue at a similar pace in the months ahead,” said Dagmar Schwertner-Knoll, Marketing Director of BioGenes. “The next milestone is the development of pre-optimized HCP assay kits for more reliable host cell protein detection.”

Advertisement